
NYSEFinancial ServicesAsset Management
أحدث البيانات المتاحة
4.70 US$
−0.01 US$ · -0.21%
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
الإغلاق السابق
4.70 US$
−0.01 US$ · -0.21%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
نطاق اليوم
السعر الحالي 4.70 US$
نطاق 52 أسبوعًا
السعر الحالي 4.70 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
77
أقل من القيمة
المشاعر
47
مختلط
المخاطر
53
مخاطر أعلى من المعتاد
الزخم
28
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
نطاق اليوم
السعر الحالي 4.70 US$
نطاق 52 أسبوعًا
السعر الحالي 4.70 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 97.21 مليون USD | 71.19 مليون USD | 5.97 مليون USD | 13.4 مليون USD | 100.74 مليون USD |
| تكلفة البضاعة المباعة | 16.03 مليون USD | 25.66 مليون USD | 33.04 مليون USD | 22.9 مليون USD | 13.39 مليون USD |
| الربح الإجمالي | 81.18 مليون USD | 45.53 مليون USD | −27.07 مليون USD | −9.51 مليون USD | 87.35 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 6.12 مليون USD | 8.69 مليون USD | 9 مليون USD | 6.7 مليون USD | 6.13 مليون USD |
| نفقات التشغيل | 5.45 مليون USD | 13.49 مليون USD | 12.75 مليون USD | 10.56 مليون USD | 10.79 مليون USD |
| دخل الفوائد | 88.26 مليون USD | 106.38 مليون USD | 133.25 مليون USD | 116.57 مليون USD | 82.83 مليون USD |
| مصاريف الفوائد | 26.52 مليون USD | 25.66 مليون USD | 33.04 مليون USD | 22.9 مليون USD | 13.39 مليون USD |
| الاستهلاك والإطفاء | — | — | — | 2.04 مليون USD | 1.96 مليون USD |
| الدخل التشغيلي | 75.73 مليون USD | 32.05 مليون USD | −39.82 مليون USD | −20.07 مليون USD | 76.56 مليون USD |
| صافي الدخل | 49.21 مليون USD | 32.05 مليون USD | −39.82 مليون USD | −20.07 مليون USD | 76.56 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
5.00 US$
ارتفاع محتمل بنسبة 6.38%توزيعات نقدية سنوية معدلة للسهم الواحد.
1.08 US$
2025 سنة كاملة-25.0% منذ 2021
2026 سنة جزئية: 0.75 US$
1.44 US$
2,021
1.55 US$
2,022
1.60 US$
2,023
1.40 US$
2,024
1.08 US$
2,025
0.75 US$
2,026*
* سنة تقويمية جزئية ضمن سجل توزيعات الأرباح المتاح.
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباحالقادمة | 16 ديسمبر 2026 | 0.06 US$Quarterly | 16 ديسمبر 2026 | 30 ديسمبر 2026 |
توزيعات الأرباح | 16 سبتمبر 2026 | 0.29 US$Quarterly | 16 سبتمبر 2026 | 30 سبتمبر 2026 |
توزيعات الأرباح | 16 يونيو 2026 | 0.23 US$Quarterly | 16 يونيو 2026 | 30 يونيو 2026 |
توزيعات الأرباح | 17 مارس 2026 | 0.23 US$Semi-Annual | 17 مارس 2026 | 31 مارس 2026 |
توزيعات الأرباح | 16 ديسمبر 2025 | 0.25 US$Special | 16 ديسمبر 2025 | 30 ديسمبر 2025 |
توزيعات الأرباح | 16 سبتمبر 2025 | 0.23 US$Quarterly | 16 سبتمبر 2025 | 30 سبتمبر 2025 |
استحقاق التوزيعات 16 ديسمبر 2026
0.06 US$
Quarterly
تاريخ التسجيل 16 ديسمبر 2026 · تاريخ الدفع 30 ديسمبر 2026
استحقاق التوزيعات 16 سبتمبر 2026
0.29 US$
Quarterly
تاريخ التسجيل 16 سبتمبر 2026 · تاريخ الدفع 30 سبتمبر 2026
استحقاق التوزيعات 16 يونيو 2026
0.23 US$
Quarterly
تاريخ التسجيل 16 يونيو 2026 · تاريخ الدفع 30 يونيو 2026
استحقاق التوزيعات 17 مارس 2026
0.23 US$
Semi-Annual
تاريخ التسجيل 17 مارس 2026 · تاريخ الدفع 31 مارس 2026
استحقاق التوزيعات 16 ديسمبر 2025
0.25 US$
Special
تاريخ التسجيل 16 ديسمبر 2025 · تاريخ الدفع 30 ديسمبر 2025
استحقاق التوزيعات 16 سبتمبر 2025
0.23 US$
Quarterly
تاريخ التسجيل 16 سبتمبر 2025 · تاريخ الدفع 30 سبتمبر 2025
صناديق متداولة تفصح عن تعرضها لهذا السهم.
المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.